Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-cash Items (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 14 years of Non-cash Items data on record, last reported at $6.2 million in Q4 2025.

  • For Q4 2025, Non-cash Items changed N/A year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, changed N/A, while the annual FY2025 figure was $6.2 million, N/A changed from the prior year.
  • Non-cash Items reached $6.2 million in Q4 2025 per LCTX's latest filing, down from $7.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $13.0 million in Q1 2023 and bottomed at $4000.0 in Q4 2023.
  • Average Non-cash Items over 5 years is $5.7 million, with a median of $6.9 million recorded in 2021.
  • Peak YoY movement for Non-cash Items: soared 9947.13% in 2021, then plummeted 99.92% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $219000.0 in 2021, then skyrocketed by 522.83% to $1.4 million in 2022, then plummeted by 99.71% to $4000.0 in 2023, then surged by 237400.0% to $9.5 million in 2024, then tumbled by 34.74% to $6.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $6.2 million in Q4 2025, $7.5 million in Q3 2025, and $8500.0 in Q2 2025.